Disease · MONDO_0011962
Comparisons in its trials64
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 64
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): deaths from any cause | 271 of 647 | 280 of 665 | 1,312 | NCT00063999 | Trial comparisons |
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): serious adverse events | 217 of 647 | 156 of 665 | 1,312 | NCT00063999 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced a Serious Adverse Event (SAE) | 230 of 420 | 84 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Discontinued Study Intervention Due to an AE | 203 of 420 | 80 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced an Adverse Event (AE) | 418 of 420 | 405 of 411 | 831 | NCT03884101 | Trial comparisons |
| Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin: Number of Participants Who Experienced an Immune-Related Adverse Event (irAE) | 316 of 420 | 56 of 411 | 831 | NCT03884101 | Trial comparisons |
Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel: Number of Participants Who Discontinued Study Treatment Due to a TEAE in All-comer Participants | 180 of 406 | 49 of 388 | 794 | NCT03517449 | Trial comparisons |
Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel: Number of Partricipants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs) | 237 of 406 | 121 of 388 | 794 | NCT03517449 | Trial comparisons |
| Lenvatinib 20 mg + Pembrolizumab 200 mg vs Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel: Number of Participants Who Discontinued Study Treatment Due to a TEAE in pMMR Participants | 140 of 342 | 42 of 325 | 667 | NCT03517449 | Trial comparisons |
| Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): Number of Participants With Recurrence or Death Events at Primary Analysis | 44 of 301 | 43 of 300 | 601 | NCT00807768 | Trial comparisons |
| Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): Number of Participants With Death Events | 39 of 301 | 37 of 300 | 601 | NCT00807768 | Trial comparisons |
| Arm I (Pelvic Radiation Therapy) vs Arm II (Brachytherapy, Paclitaxel, Carboplatin): serious adverse events | 9 of 283 | 32 of 290 | 573 | NCT00807768 | Trial comparisons |
| Arm 1 vs Arm 2: serious adverse events | 10 of 261 | 21 of 278 | 539 | NCT00006011 | Trial comparisons |
| AEZS-108 / Zoptarelin Doxorubicin vs Doxorubicin/ Standard Chemotherapy: deaths from any cause | 196 of 252 | 188 of 249 | 501 | NCT01767155 | Trial comparisons |
| AEZS-108 / Zoptarelin Doxorubicin vs Doxorubicin/ Standard Chemotherapy: serious adverse events | 92 of 252 | 75 of 249 | 501 | NCT01767155 | Trial comparisons |
| Arm I (Paclitaxel, Carboplatin, Metformin Hydrochloride) vs Arm II (Paclitaxel, Carboplatin, Placebo): deaths from any cause | 95 of 234 | 95 of 235 | 469 | NCT02065687 | Trial comparisons |
| Arm I (Paclitaxel, Carboplatin, Metformin Hydrochloride) vs Arm II (Paclitaxel, Carboplatin, Placebo): serious adverse events | 46 of 234 | 53 of 235 | 469 | NCT02065687 | Trial comparisons |
| Arm I (Brachytherapy, Radiation Therapy) vs Arm II (Brachytherapy, Radiation Therapy, Cisplatin): Number of Participants That Experienced Death on Study | 18 of 74 | 21 of 82 | 156 | NCT00492778 | Trial comparisons |
| Arm I (Brachytherapy, Radiation Therapy) vs Arm II (Brachytherapy, Radiation Therapy, Cisplatin): Number of Participants With Disease Progression or Death. | 27 of 74 | 35 of 82 | 156 | NCT00492778 | Trial comparisons |
| Arm I (Brachytherapy, Radiation Therapy) vs Arm II (Brachytherapy, Radiation Therapy, Cisplatin): deaths from any cause | 18 of 74 | 21 of 82 | 156 | NCT00492778 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011962/comparisons